Search - Leibniz Institute for Prevention Research and Epidemiology

241. [BIPS Project] Prescription of teratogenic substances in women of childbearing age

URL: /en/research/projects/detail-view.html?projID=795&cHash=e53a3e4ef24451010c72f5f9bb8f305e
Date: 01-02-19

A project description will follow shortly.

242. [BIPS Project] Prescription behavior of HIV therapeutics in women of childbearing age and during pregnancy in Germany

URL: /en/research/projects/detail-view.html?projID=974&cHash=d5e90c4345002941d700ed7dbe9d8ae4
Date: 01-01-22

Prescription of HIV therapeutics in women of childbearing age and during pregnancy in Germany At the end of 2019, there were approximately 80,000 persons with a diagnosed infection with the human…

243. [BIPS Project] Prenatal and childhood immunization and the risk of childhood cancer

URL: /en/research/projects/detail-view.html?projID=929&cHash=5c5d02187aab30716f818fc2224b4c82
Date: 01-10-22

Risk factors for most childhood cancers are unknown. Currently, there are some protective factors acting via immunological pathways, like infections and particularly vaccinations, under discussion.…

244. [BIPS Project] Post-marketing drug utilization study for galcanezumab

URL: /en/research/projects/detail-view.html?projID=827&cHash=69f47eb761baaa0a1cab27c240e33036
Date: 01-03-19

Galcanezumab is a humanised monoclonal antibody against human calcitonin gene-related peptide and is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month…

245. [BIPS Project] Post-authorization safety study on agomelatine and the risk of hospitalization for acute liver injury

URL: /en/research/projects/detail-view.html?projID=614&cHash=d6fb320a906b37e1962b34f47eea3ffd
Date: 15-08-14

Agomelatine (Valdoxan, Thymanax) is a melatonergic agonist and 5-HT2C antagonist which is, among other antidepressants, indicated for major depressive episodes in adults. Its marketing authorisation…

246. [BIPS Project] Post-authorisation safety study of tralokinumab use in pregnancy

URL: /en/research/projects/detail-view.html?projID=1040&cHash=61d281ea60f3f02b443b69dfb3b9577a
Date: 01-01-23

Tralokinumab is a biological agent developed for the treatment of moderate to severe atopic dermatitis (AD) and is administered by subcutaneous injection. Tralokinumab is a fully human immunoglobulin…

247. [BIPS Project] Post-authorisation safety study of nocdurna for the symptomatic treatment of nocturia due to idiopathic nocturnal polyuria: A multi-country cohort study using secondary data

URL: /en/research/projects/detail-view.html?projID=917&cHash=f3708b280935a2f6fdb046a4bcf0808f
Date: 17-11-20

Nocdurna (desmopressin) has been approved in Germany since January 2017 for the treatment of nocturia in adult patients with idiopathic nocturnal polyuria. Desmopressin is an analog of the…

248. [BIPS Project] Pooled analysis of European case-control studies on the interaction of occupational carcinogens in the development of lung cancer

URL: /en/research/projects/detail-view.html?projID=255&cHash=9467fe697f13e1339ae60e26527d392f
Date: 01-04-07

The SYNERGY project -a pooled analysis of case-control studies on the joint effects of occupational carcinogens in the development of lung cancer- began in January 2007. The aim of SYNERGY is to…

249. [BIPS Project] Policy evaluation network - Public policies addressing health-related behaviours in Europe

URL: /en/research/projects/detail-view.html?projID=740&cHash=9352f80adcf9237e1653479c9373a2f8
Date: 01-02-19

Non-communicable diseases (NCDs) are the leading cause of global mortality, responsible for 41 million deaths each year. Successful policy actions to address physical inactivity, unhealthy diets, and…

250. [BIPS Project] Pilot project for the cross-sectoral implementation of a comprehensive and quality-tested sports and exercise therapy for cancer

URL: /en/research/projects/detail-view.html?projID=964&cHash=f8145541a2c5c50f087758bbfee9fdd4
Date: 01-03-23

IMPLEMENT aims to develop, test and establish a sustainable access structure for quality-assured oncological exercise therapy in Germany as a model within the funding period of three years. In the…